ATOS vs. NKTR, ACET, PRQR, RLMD, KPTI, GLYC, SYRE, IMRX, GTHX, and RANI
Should you be buying Atossa Therapeutics stock or one of its competitors? The main competitors of Atossa Therapeutics include Nektar Therapeutics (NKTR), Adicet Bio (ACET), ProQR Therapeutics (PRQR), Relmada Therapeutics (RLMD), Karyopharm Therapeutics (KPTI), GlycoMimetics (GLYC), Spyre Therapeutics (SYRE), Immuneering (IMRX), G1 Therapeutics (GTHX), and Rani Therapeutics (RANI). These companies are all part of the "pharmaceutical preparations" industry.
Atossa Therapeutics (NASDAQ:ATOS) and Nektar Therapeutics (NASDAQ:NKTR) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, valuation, analyst recommendations, earnings, media sentiment, institutional ownership, community ranking, risk and dividends.
Atossa Therapeutics has higher earnings, but lower revenue than Nektar Therapeutics. Atossa Therapeutics is trading at a lower price-to-earnings ratio than Nektar Therapeutics, indicating that it is currently the more affordable of the two stocks.
Nektar Therapeutics received 401 more outperform votes than Atossa Therapeutics when rated by MarketBeat users. Likewise, 70.61% of users gave Nektar Therapeutics an outperform vote while only 64.76% of users gave Atossa Therapeutics an outperform vote.
In the previous week, Atossa Therapeutics had 5 more articles in the media than Nektar Therapeutics. MarketBeat recorded 5 mentions for Atossa Therapeutics and 0 mentions for Nektar Therapeutics. Nektar Therapeutics' average media sentiment score of 0.65 beat Atossa Therapeutics' score of 0.41 indicating that Nektar Therapeutics is being referred to more favorably in the news media.
Atossa Therapeutics has a beta of 1.16, meaning that its share price is 16% more volatile than the S&P 500. Comparatively, Nektar Therapeutics has a beta of 0.86, meaning that its share price is 14% less volatile than the S&P 500.
Atossa Therapeutics currently has a consensus target price of $4.50, suggesting a potential upside of 248.84%. Nektar Therapeutics has a consensus target price of $3.50, suggesting a potential upside of 311.76%. Given Nektar Therapeutics' higher possible upside, analysts plainly believe Nektar Therapeutics is more favorable than Atossa Therapeutics.
Atossa Therapeutics has a net margin of 0.00% compared to Nektar Therapeutics' net margin of -306.31%. Atossa Therapeutics' return on equity of -24.80% beat Nektar Therapeutics' return on equity.
12.7% of Atossa Therapeutics shares are held by institutional investors. Comparatively, 82.2% of Nektar Therapeutics shares are held by institutional investors. 7.8% of Atossa Therapeutics shares are held by company insiders. Comparatively, 3.1% of Nektar Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Summary
Atossa Therapeutics beats Nektar Therapeutics on 10 of the 17 factors compared between the two stocks.
Get Atossa Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for ATOS and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ATOS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartThis chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
Atossa Therapeutics Competitors List
Related Companies and Tools